Chemokines as markers for parasite-induced inflammation and tumors

International Journal of Biological Markers

Volumn 20, Issue 4, 2005, Pages 197-203

  Trakatelli, C ^a   Frydas, S ^b   Hatzistilianou, M ^c   Papadopoulos, E ^b   Simeonidou, I ^b   Founta, A ^d   Paludi, D ^e   Petrarca, C ^f   Castellani, M L ^f   Papaioannou, N ^b   Salini, V ^f   Conti, P ^f   Kempuraj, D ^g   Vecchiet, Jacopo ^f  

^a Georgios Gennimatas General Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d ALEXANDER TECHNOLOGICAL EDUCATIONAL INSTITUTE OF THESSALONIKI   (Greece)

^e UNIVERSITY OF TERAMO   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g TUFTS UNIVERSITY   (United States)

Author keywords

Chemokines; Cytokine; Inflammation; Markers; Parasitic disease

Indexed keywords

ALPHA CHEMOKINE; AMPHIREGULIN; BETA CHEMOKINE; BETA2 INTEGRIN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CHEMOKINE; CX3C CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; RANTES; RECOMBINANT PROTEIN; RECOMBINANT RANTES; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CANCER; CARCINOGENESIS; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE MARKER; DISEASE SEVERITY; ECHINOCOCCUS GRANULOSUS; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION RESISTANCE; INFLAMMATION; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; LEUKOCYTE FUNCTION; NONHUMAN; PARASITOSIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN LEISHMANIASIS; TOXOPLASMOSIS; TRYPANOSOMA CRUZI;

ANIMALIA; ECHINOCOCCUS GRANULOSUS; TRYPANOSOMA CRUZI;

EID: 30844459260     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080502000401     Document Type: Review

References (68)

1. Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivol basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89: 4120-7.
2. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-41.
3. Conti P, Reale M, Barbacane RC, Letourneau R, Theoharides TC. Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/WV mice. FASEB J 1998; 12: 1693-700.
4. Appert-Collin A, Duong FH, Passilly Degrace P, et al. Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells. Int J Immunopathol Pharmacol 2005; 18: 233-44.
5. Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 2004; 17: 401-6.
6. Ballerini P, Di Iorio P, Ciccarelli R, et al. P2Y1 and cysteinyl-leukotriene receptors mediate purine and cysteinyl-leukotriene co-release in primary cultures of rat microglia. Int J Immunopathol Pharmacol 2005; 18: 255-68
7. Prosperi C, Scali C, Barba M, Bellucci A, Giovannini MG, Pepeu G, Casamenti F. Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta (1-42)-induced brain inflammation and neuronal damage in the rat. Int J Innunopathol Pharmacol 2004; 17: 317-30.
8. Trubiani O, Di Primio R, Traini T, et al. Morphological and cytofluorimetric analysis of adult mesenchymal stem cells expanded ex vivo from periodontal ligament. Int J Immunopathol Pharmacol 2005; 18: 213-22.
9. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
10. Kempuraj D, Frydas S, Karagouni E, et al. Cytokines and the brain. Int J Immunopathol Pharmacol 2004; 17: 229-32.
11. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. New Engl J Med 1998; 338: 436-45.
12. Huang SH, Frydas S, Conti P, et al. Interleukin-17: a revisited study. Int J Immunopathol Pharmacol 2004; 17: 1-8.
13. Cavalieri S, Rotoli M, Feliciani C, Amerio P. Expression of the high-affinity laminin receptor (67 kDa) in normal human skin and appendages. Int J Immunopathol Pharmacol 2005; 18: 223-32.
14. Petrarca C, Frydas S, Donelan J, et al. Interleukin 27 (IL-27): a novel pleiotropic cytokine involved in T cell differentiation and T cell response modulation. Int J Immunopathol Pharmacol 2005; 18: 191-4.
15. Frydas S, Karagouni E, Hatzistilianou M, et al. Cytokines and allergic disorders: a revised study. Int J Immunopathol Pharmacol 2004; 17: 233-6.
16. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 21: 593-620.
17. Von Andrian UH, Mackay C. T-cell function and migration. Two sides of the same coin. New Engl J Med 2000; 343: 1020-34.
18. Conti P, Pang X, Boucher W. RANTES is a pro-inflammatory chemokine and chemoattracts basophil cells to extravascular sites. J Pathol 1997; 183: 352-8.
19. Tsagozis P, Karagouni E, Dotsika E. Dendritic cells pulsed with pepticles of gp63 induce differential protection against experimental cutaneous leishmaniasis. Int J Immunopathol Pharmacol 2004; 17: 343-52.
20. Lukacs NN, Strieter RM, Warmington K, Lincoln P, Chensue SW, Kunkel SL. Differential recruitment of leukocyte populations and alteration of airway hyperreactivity by C-C family chemokines in allergic airway inflammation. J Immunol 1997; 158: 4398-404.
21. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1-12.
22. Kalyanaraman M, Heidemann SM, Samaik AP. Macrophage inflammatory protein-2 predicts acute lung injury in endotoxemia. J Investig Med 1998; 46: 275-8.
23. Kempuraj D, Donelan J, Frydas S, Iezzi T, Conti F, Boucher W, Papadopoulou NG, Madhappan B, Letourneau L, Cao J, Sabatino G, Meneghini F, Stellin L, Verna N, Riccioni G, Theoharides TC. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int J immunopathol Pharmacol 2004; 17: 103-6.
24. Pannellini T, Iezzi M, Di Carlo E, Eleuterio E, Coletti A, Modesti A, Rosini S, Neri M, Musiani P. The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis. Int J Immunopathol Pharmacol 2004; 17: 171-80.
25. Avgerinos DV, Theoharides TC. Mesenteric traction syndrome or gut in distress. Int J Immunopathol Pharmacol 2005; 18: 195-200.
26. Ross R, Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
27. Yan XT, Tumpey TM, Kunkel SL, Oakes JE, Lausch RN. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1 -infected cornea. Invest Ophthalmol Vis Sci 1998; 39: 1854-62.
28. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 1995; 270: 11703-6.
29. Martini F, Agrati C, D'Offizi G, Poccia F. HLA-E up-regulation induced by HIV infection may directly contribute to CD94-mediated impairment of NK cells. Int J Immunopathol Pharmacol 2005; 18: 269-76.
30. Alexandrakis MG, Passam FH, Pappa CA, et al. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-α in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int J Immunopathol Pharmacol 2005; 18: 287-96.
31. Centurione L, Di Giulio C, Santavenere E, et al. Protein kinase C zeta regulation of hypertrophic and apoptotic events occurring during rat neonatal heart development and growth. Int J Immunopathol Pharmacol 2005; 18: 49-58.
32. van Zandbergen G, Hermann N, Laufs H, Solbach W, Laskay T. Leishimania promastigotes release a granulocyte chemotactic factor and induce interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by neutrophil granulocytes. Infect Immun 2002; 70: 4177-84.
33. Brandonisio O, Panaro MA, Fumarola I, et al. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med 2002; 2: 125-9.
34. Kempuraj D, Devi RS, Madhappan B, Conti P, Nazer MY, Christodoulou S, Reginald J, Suthinthirarajan N, Namasivayam A. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol 2004; 17: 57-64.
35. Cognasse F, Chavarin P, Acquari S, et al. Differential downstream effects of ligation mediated by membrane or soluble CD40L and agnostic Ab: a study on purified human B cells. Int J Immunopathol Pharmacol 2005; 18: 65-74.
36. Ji J, Sun J, Soong L. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensi. Infect Immun 2003; 71: 4278-88.
37. Marchisio M, Grimley PM, Di Baldassarre A, Santavenere E, Miscia S. Novel shift of Jak/Stat signalling characterizes the protective effect of aurintricarboxylic acid (ATA) from tumor necrosis factor-alpha toxicity in human B lymphocytes. Int J Immunopathol Pharmacol 2004; 17: 5-14.
38. Ritter U, Moll H, Laskay T, et al. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. J Infect Dis 1996; 173: 699-709.
39. Ritter U, Moll H. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-γ and is antagonized by IL-4. Eur J Immunol 2000; 30: 3111-20.
40. Matte C, Olivier M. Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators. J Infect Dis 2002; 185: 673-81.
41. Ohmori Y, Wyner L, Narumi S, Armstrong D, Stoler M, Hamilton TA. Tumor necrosis factor-α induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am J Pathol 1993; 142: 861-70.
42. Aliberti JC, Machado FS, Souto JT, et al. Beta-chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun 1999; 67: 4819-26.
43. Lima MF, Zhang Y, Villalta F. Beta-chemokines that inhibit HIV-1 infection of human macrophages stimulate uptake and promote destruction of Trypanosoma cruzi by human macrophages. Cell Mol Biol 1997; 43: 1067-76.
44. Sharafeldin A, Eltayeb R, Pashenkov M, Bakhiet M. Chemokines are produced in the brain early during the course of experimental Africa trypanosomiasis. J Neuroimmunol 2000; 103: 165-70.
45. Bliss SK, Marshall AJ, Zhang Y, Denkers EY. Human polymorphonuclear leukocytes produce IL-12, TNF-alpha and the chemokines macrophage-inflammatory protein-1 alpha and -1 beta in response to Toxoplasma gondii antigen. J Immunol 1999; 162: 7369.
46. Kim JM, Oh YK, Kim YJ, Cho SJ, Ahn MH, Cho YJ. Nuclear factor kappa B plays a major role in the regulation of Hela cells in response to Toxoplasma gondii infection. Parasitol Res 2001; 87: 758-63.
47. Rossi RE, Monasterolo G. A pilot study of feasibility of ultrarush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005; 18: 277-86.
48. Musso T, Cappello P, Stornello S, et al. IL-b enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes. Int J Immunopathol Pharmacol 2005; 18: 339-50.
49. Theodorides Y, Frydas S, Rallis T, et al. MCP-1 and MIP-2 levels during Echinococus granulosus infections in mice. J Helminth 2001; 75: 205-8.
50. Reale M, Frydas S, Barbacane RC, et al. Induction of monocyte chemotactic protein (MCP-1) and TNF alpha by Trichinella spiralis in serum of mice in vivo. Mol Cell Biochem 1998; 179: 1-8.
51. Trubiani O, Guarnieri S, Orciani M, Salvolini E, Di Primio R. Sphingolipid microdomains mediate CD38 internalization: topography of the endocytosis. Int J Immunopathol Pharmacol 2004; 17: 293-300.
52. Appert-Collin A, Duong FHT, Passilly Degrace P, Waiter J-M, Poindron P, Gies J-P. MAPK activation via 5-hydroxy-tryptamine 1A receptor is involved in the neuroprotective effects of xaliproden. Int J Immunopathol Pharmacol 2005; 18: 21-32.
53. Di Giannantonio M, Frydas S, Kempuraj D, et al. Cytokines in stress. Int J Immunopathol Pharmacol 2005; 18: 1-6.
54. Cassano N, Loconsole F, Amoruso A, et al. Infliximab monotherapy for refractory psoriasis: preliminary results. Int J Immunopathol Pharmacol 2004; 17: 373-80.
55. Theoharides TC, Sant GR. A pilot open label study of Cystoprotek® in interstitial cystitis. Int J Immunopathol Pharmacol 2005; 18: 183-8.
56. Frydas S, Papaioannou N, Papazahariadou M, et al. Inhibition of MCP-1 and MIP-2 chemokines in murine trichinellosis: effect of the anti-inflammatory compound I-mimosine. Int J Immunopathol Pharmacol 2005; 18: 85-94.
57. Leggio L, Addolorato G, Abenavoli L Gasbarrini C. Wilson's disease: clinical, genetic and pharmacological findings. Int J Immunopathol Pharmacol 2005; 18: 7-14
58. Guidi L, Costanzo M, Ciarniello M, et al. Increased levels of NF-kB inhibitors (IκBα and IκBγ) in the intestinal mucosa of Crohn's disease patients during infliximab treatment. Int J Immunopathol Pharmacol 2005; 18: 155-64.
59. Totaro R, Passacantando A, Russo T, et al. Effects of interferon beta, cyclophosphamide, and azathioprine on cytokine profile in patients with multiple sclerosis. Int J Immunopathol Pharmacol 2005; 18: 377-384.
60. Somma P, Lo Muzio L, Mansueto C, et al. Squamous cell carcinoma of the lower lip: Fas/FasL expression, lymphocyte subtypes and outcome. Int J Immunopathol Pharmacol 2005; 18: 59-64.
61. Cognasse F, Chavarin P, Acquari S, et al. Differential downstream effects of ligation mediated by membrane or soluble CD40L and agnostic Ab: a study on purified human B cells. Int J Immunopathol Pharmacol 2005; 18: 65-74.
62. Falkensammer B, Fasser W, Scherer K, et al. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. Int J Immunopathol Pharmacol 2005; 18: 145-54.
63. Yamaki K, Uchida H, Li X, et al. Effect of varying types of anti-arthritic drugs on Th1 and Th2 immune responses in mice. Int J Immunopathol Pharmacol 2005; 18: 133-44.
64. Shrivastava P, Singh SM, Singh N. Activation of tumor-associated macrophages by thymosin alpha 1. Int J Immunopathol Pharmacol 2004; 17: 39-47.
65. Conti P, Reale M, Nicolai M, et al. Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients. Cancer Immunol Immunother 1994; 38: 365-71.
66. Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, Fiore S. Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol 2004; 17: 145-56.
67. Appert-Collin A, Duong FH, Passilly-Degrace P, Gies JP, Warter JM, Poindron P. Quantification of neurotrophin mRNA expression in PMN mouse: modulation by xaliproden. Int J Immunopathol Pharmacol 2004; 17: 157-64.
68. Cross ML. Immune-signalling by orally-delivered probiotic bacteria: effects on common mucosal immunoresponses and protection at distal mucosal sites. Int J Immunopathol Pharmacol 2004; 17: 127-34.